By admin 
The annual congress of the European Society of Cardiology (ESC), a preeminent global event in cardiovascular medicine, recently concluded, serving as a critical platform for the dissemination of groundbreaking clinical trial results. Over the weekend, leading pharmaceutical and biotechnology companies unveiled comprehensive data from studies evaluating novel therapies for a spectrum of heart conditions, triggering significant discussions among clinicians, researchers, and investors alike. These presentations, particularly those featured in the highly anticipated "Hot Line" sessions, often set the tone for future treatment guidelines and market trajectories within the cardiovascular therapeutic landscape. BioPharma Dive is highlighting three particularly notable datasets, examining their scientific implications and the immediate reactions from the financial community.
The ESC Congress, typically held in late August or early September, is the world’s largest and most influential cardiology meeting, drawing tens of thousands of cardiologists, scientists, nurses, allied health professionals, and industry representatives from across the globe. Its significance lies in its role as a nexus for translating cutting-edge research into clinical practice, fostering collaboration, and shaping the future of heart health. The detailed data presented often provide crucial context to preliminary announcements, allowing for a deeper understanding of a drug’s efficacy, safety profile, and its potential positioning within an evolving treatment paradigm.
Cytokinetics and Myqorzo: Navigating Efficacy and Safety in Hypertrophic Cardiomyopathy
One of the most keenly watched updates concerned Cytokinetics’ investigational drug, Myqorzo (aficamten), for hypertrophic cardiomyopathy (HCM). HCM is a chronic, progressive genetic heart disease characterized by excessive thickening of the heart muscle, leading to impaired blood flow and potentially life-threatening complications like heart failure, arrhythmias, and sudden cardiac death. Historically, treatment has focused on symptom management and surgical intervention, with limited targeted pharmacological options. The condition manifests in two primary forms: obstructive HCM (oHCM), where the thickened muscle obstructs blood flow, and non-obstructive HCM (nOHCM), where no significant obstruction occurs, but the heart muscle is still abnormal and stiff, leading to diastolic dysfunction and heart failure symptoms. Approximately one-third of HCM patients have the non-obstructive form, for which specific therapeutic options have been virtually non-existent, representing a significant unmet medical need.
In June, Cytokinetics announced a major clinical triumph: Myqorzo succeeded in its Phase 3 ACACIA-HCM trial in patients with nOHCM. This initial disclosure positioned Myqorzo as a potential first-in-class therapy to demonstrate benefit across both forms of HCM, setting it apart from Bristol Myers Squibb’s (BMS) market-leading medicine, Camzyos (mavacamten), which is currently approved only for oHCM. Both Myqorzo and Camzyos are cardiac myosin inhibitors, a novel class of drugs designed to reduce the excessive contractility of the heart muscle characteristic of HCM.
The detailed findings from the ACACIA-HCM study were a focal point at the ESC Congress, presented in a "Hot Line" session, and simultaneously published in the prestigious New England Journal of Medicine on Friday. The data reinforced Myqorzo’s compelling efficacy. Patients randomized to receive Myqorzo demonstrated a statistically significant and clinically meaningful average 11.4-point improvement on the Kansas City Cardiomyopathy Questionnaire (KCCQ-CSS), a widely used patient-reported outcome measure assessing heart health, after 36 weeks of treatment. This compared favorably to an 8.4-point change observed in placebo recipients. Furthermore, treated patients experienced an improvement in peak oxygen consumption (pVO2), a key measure of functional capacity, while those in the placebo group saw a slight decline. The improvements in KCCQ-CSS scores and pVO2 underscore Myqorzo’s ability to enhance both symptoms and exercise capacity in nOHCM patients.
Wall Street analysts largely lauded these results, with Leerink Partners analyst Roanna Ruiz noting that Myqorzo’s effects were "consistent" across all analyzed study groups, "reiterating" Cytokinetics’ initial positive findings. Stifel’s James Condulis echoed this sentiment, emphasizing the "robust" efficacy data and highlighting that the drug’s impact on assessment scores appeared to progressively grow over time, suggesting sustained and potentially increasing benefit with longer treatment duration.
Despite the strong efficacy data, Cytokinetics’ shares experienced a notable decline of over 7% on Friday. The catalyst for this sell-off was the disclosure within the NEJM paper that 10 patients receiving Myqorzo experienced a specific kind of heart failure event – described as "left ventricular systolic dysfunction" – compared to only three patients in the placebo arm. This finding immediately raised a "lingering debate" about the safety profile of cardiac myosin inhibitors, particularly in the context of non-obstructive disease where the hemodynamic profile is different from oHCM. While cardiac myosin inhibitors are designed to reduce hypercontractility, excessive reduction can lead to ventricular dysfunction, requiring careful monitoring and dose adjustments.
However, many analysts urged a nuanced interpretation. Condulis and others argued that the overall evidence still strongly supports a new regulatory approval for Myqorzo and anticipates broader clinical uptake, especially given the significant unmet need in nOHCM. Mizuho Securities analyst Salim Syed pointed out a critical detail often overlooked by the market in its immediate reaction: there were no deaths reported among Myqorzo-treated patients during the study period, whereas three deaths occurred in the placebo arm. Syed succinctly encapsulated the market’s initial reaction as "like missing [the] forest for trees," emphasizing the profound benefit of having any targeted therapy for nOHCM, a patient population currently with "essentially zero options." Cytokinetics is expected to leverage these compelling efficacy results to file a New Drug Application (NDA) with regulatory bodies in the coming months, aiming to bring Myqorzo to patients who desperately need it.
Arrowhead Pharmaceuticals and Plozasiran: A New Contender in Severe Hypertriglyceridemia
The ESC Congress also provided a deeper look into the intensifying rivalry in the treatment of severe hypertriglyceridemia (sHTG), a condition characterized by extremely high levels of triglycerides in the blood, significantly increasing the risk of acute pancreatitis and cardiovascular events. This arena is currently seeing a heated competition between Arrowhead Pharmaceuticals and Ionis Pharmaceuticals, a battle that initially began in the rarer familial chylomicronemia syndrome.
Arrowhead Pharmaceuticals’ plozasiran, an investigational RNA interference (RNAi) therapeutic, took center stage with detailed data from its Phase 3 SHASTA-3 and SHASTA-4 studies in adults with sHTG. In July, Arrowhead had announced that plozasiran met its primary objectives in these late-stage trials. The ESC presentation provided the granular data that analysts and clinicians had been awaiting, setting the stage for plozasiran to directly challenge Ionis’s Tryngolza (olezarsen), an antisense oligonucleotide (ASO) drug that secured FDA approval for sHTG in June.
Analysts quickly moved to compare the two drugs, and the consensus emerging from ESC favored plozasiran, particularly on its safety profile. Prakhar Agrawal of Cantor Fitzgerald highlighted that plozasiran appears safer "across several metrics," including lower rates of adverse events leading to study discontinuations and, crucially, a more favorable impact on liver enzymes and liver fat increases – a key area of investor and regulatory scrutiny for lipid-lowering therapies. While both drugs effectively lower triglyceride levels, their mechanisms of action differ: plozasiran utilizes RNAi to silence genes involved in triglyceride production, while Tryngolza uses ASO technology to achieve a similar outcome.
Though direct head-to-head trials are absent, cross-trial comparisons provided compelling insights. Agrawal noted that among patients who underwent specialized imaging tests in Arrowhead’s trials, plozasiran recipients experienced an approximate 1.5% placebo-adjusted increase in liver fat. This compared favorably to increases of 2% or even 4% observed for Tryngolza recipients in Ionis’s studies. While specialists consulted by Agrawal suggested that the liver fat increases reported for Ionis’s drug "may not be clinically meaningful" from a purely clinical standpoint, his team nonetheless anticipates that this perceived safety advantage will be a significant factor in plozasiran’s market positioning, potentially making it the preferred therapeutic option for many clinicians. Stifel’s Condulis echoed this sentiment, writing that plozasiran’s results "arguably support a best-in-class profile."
Arrowhead’s strategic timeline includes filing for regulatory approval by the end of the current year, which could pave the way for a commercial launch as early as 2027. The market opportunity for sHTG is substantial, with Agrawal projecting that the global market could reach $6 billion by 2035. Given its perceived safety edge, plozasiran is anticipated to capture a dominant share, potentially claiming 60% of this burgeoning market. This competitive dynamic is set to drive significant innovation and improved patient outcomes in the management of severe hypertriglyceridemia.
The Eplontersen Autopsy: Rethinking ATTR-CM Treatment Strategies
Perhaps one of the most anticipated "autopsies" of a clinical trial failure at ESC involved eplontersen, a drug developed by AstraZeneca and Ionis Pharmaceuticals for transthyretin amyloidosis-mediated cardiomyopathy (ATTR-CM). In July, the industry was stunned by the announcement that eplontersen missed the central objective of its Phase 3 study in this progressive and deadly heart condition. ATTR-CM is caused by the misfolding and aggregation of transthyretin (TTR) protein, which deposits as amyloid fibrils in the heart, leading to restrictive cardiomyopathy, heart failure, and high mortality rates. Treatment strategies generally involve "silencers" (which reduce the production of TTR protein) and "stabilizers" (which prevent TTR protein from misfolding).
The ESC Congress provided the first detailed presentation of the eplontersen Phase 3 data, offering critical insights into why the drug failed to meet its primary composite endpoint of all-cause mortality and recurrent cardiovascular events. This detailed dissection of the trial results immediately spurred Wall Street analysts to re-evaluate the implications for other companies with rival medicines in the ATTR-CM space.
Alnylam Pharmaceuticals, a leader in RNAi therapeutics, already markets Amvuttra (vutrisiran), a TTR silencer, which, like eplontersen, aims to reduce TTR protein production. Alnylam also has a next-generation TTR silencer, nucresiran (ALN-TTRsc04), in late-stage testing. Eplontersen’s failure, an ASO therapeutic, inevitably cast a shadow of doubt over the efficacy and impact of TTR silencers in general, raising skepticism not only about Amvuttra’s full potential in ATTR-CM but also about nucresiran’s chances of success.
William Blair analyst Myles Minter highlighted that the AstraZeneca and Ionis findings raise fundamental questions about the benefits of combination therapy in ATTR-CM. The standard of care often involves protein "stabilizers," such as Pfizer’s Vyndamax (tafamidis) and BridgeBio Pharma’s Attruby (acoramidis). The debate now centers on whether adding TTR "silencer" drugs provides incremental benefit when patients are already on optimal stabilizer therapy, or if certain silencers are potent enough to stand alone or in specific combinations. Minter noted that these results "fuel debate around the positioning of available therapies" within this complex treatment algorithm.
Mizuho’s Salim Syed presented an intriguing analysis, suggesting that the eplontersen data "increases [the] gap" between stabilizers and silencers, effectively bolstering the case for BridgeBio’s Attruby. Syed observed that in the placebo arm of the failed eplontersen trial, a majority of patients were already receiving Vyndamax, a well-established stabilizer. However, the level of protein stabilization observed in this placebo group was notably "well short" of what had been demonstrated in trials of Attruby. Syed argued that these results underscore "why a practitioner would choose Attruby" over Vyndamax – particularly as Vyndamax approaches its patent cliff in 2031, paving the way for generics. This analysis suggests that investors may be "modeling Attruby too conservatively" in their long-term forecasts.
In contrast, analysts at Oppenheimer rallied to Alnylam’s defense, emphasizing "modality differences" between Alnylam’s RNAi drugs and Ionis’s ASO therapies. Oppenheimer’s Kostas Biliouris contended that new analyses presented by Alnylam at ESC suggest Amvuttra may be more potent than eplontersen, and that nucresiran, Alnylam’s next-generation candidate, might perform even better in its ongoing Phase 3 testing. The core of this argument lies in the distinct mechanisms: Alnylam’s drugs employ RNA interference, a process that targets messenger RNA to prevent protein production, while Ionis’s drugs utilize antisense oligonucleotide therapy, which also targets RNA but through a different molecular pathway. These mechanistic differences can lead to varying degrees of TTR protein knockdown, potency, and potentially different safety profiles, influencing clinical outcomes. The eplontersen failure, therefore, might be more specific to its modality and potency rather than a broad indictment of all TTR silencers.
Broader Market Reactions and Future Outlook for Cardiovascular Innovation
The updates from the ESC Congress underscore the dynamic and often unpredictable nature of drug development, particularly in complex and life-threatening cardiovascular conditions. The delicate balance between demonstrating robust efficacy and ensuring an acceptable safety profile remains paramount for regulatory approval and clinical adoption. Cytokinetics’ experience with Myqorzo highlights how investor sentiment can be acutely sensitive to safety signals, even when offset by significant efficacy and unmet need. Conversely, Arrowhead’s plozasiran demonstrated how a perceived safety advantage, even in cross-trial comparisons, can be a potent differentiator in a competitive market. The detailed autopsy of eplontersen’s failure further illustrated the profound implications of trial outcomes, reshaping therapeutic strategies and igniting debates on the optimal use of existing and emerging treatments for devastating conditions like ATTR-CM.
The ESC Congress serves as a powerful reminder that cardiovascular innovation continues at a rapid pace, driven by novel scientific modalities like RNAi and ASO therapies. As researchers continue to unravel the intricate pathophysiology of heart diseases, the pipeline of targeted therapies grows. The insights gleaned from these pivotal presentations will undoubtedly influence clinical practice, guide future research directions, and redefine the competitive landscape for years to come, ultimately aiming to improve the lives of millions suffering from cardiovascular ailments worldwide.
